Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-၀.၂၁%
၁,၀၉၁.၅၁
-၂.၃၀
-၀.၂၁%
—၁,၀၉၃.၈၁၁,၀၉၆.၅၂၁,၁၀၀.၂၂၁,၀၉၁.၅၁——
SIXC
Communications
SIXC
Communications
SIXC
+၀.၂၂%
၆၁၀.၁၁
+၁.၃၄
+၀.၂၂%
—၆၀၈.၇၇၆၀၈.၇၇၆၁၂.၉၇၆၀၈.၇၇——
SIXE
Energy
SIXE
Energy
SIXE
-၁.၃၄%
၁,၂၃၇.၉၈
-၁၆.၈၃
-၁.၃၄%
—၁,၂၅၄.၈၁၁,၂၅၃.၀၁၁,၂၅၃.၈၇၁,၂၂၆.၃၃——
SIXI
Industrials
SIXI
Industrials
SIXI
-၀.၉၃%
၁,၇၄၄.၇၁
-၁၆.၄၀
-၀.၉၃%
—၁,၇၆၁.၁၁၁,၇၆၄.၂၇၁,၇၆၆.၈၈၁,၇၄၄.၇၁——
SIXM
Financials
SIXM
Financials
SIXM
-၀.၃၇%
၆၄၀.၁၈
-၂.၄၀
-၀.၃၇%
—၆၄၂.၅၈၆၄၄.၈၇၆၄၈.၄၈၆၄၀.၁၈——
SIXR
Staples
SIXR
Staples
SIXR
-၀.၁၈%
၈၄၉.၅၈
-၁.၅၅
-၀.၁၈%
—၈၅၁.၁၃၈၅၅.၆၆၈၅၈.၇၅၈၄၅.၅၆——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-၀.၂၃%
၂၁၇.၄၈
-၀.၅၀
-၀.၂၃%
—၂၁၇.၉၈၂၁၇.၉၈၂၁၈.၆၅၂၁၆.၈၈——
SIXT
Technology
SIXT
Technology
SIXT
+၁.၅၂%
၃,၂၆၀.၆၉
+၄၈.၈၆
+၁.၅၂%
—၃,၂၁၁.၈၃၃,၂၂၇.၂၁၃,၂၆၈.၃၈၃,၂၂၆.၅၅——
SIXU
Utilities
SIXU
Utilities
SIXU
-၀.၆၉%
၉၄၂.၄၅
-၆.၅၃
-၀.၆၉%
—၉၄၈.၉၈၉၄၈.၅၈၉၅၇.၈၃၉၄၁.၉၇——
SIXV
Health care
SIXV
Health care
SIXV
-၀.၅၂%
၁,၄၆၆.၈၀
-၇.၇၂
-၀.၅၂%
—၁,၄၇၄.၅၂၁,၄၇၉.၀၃၁,၄၈၁.၀၄၁,၄၆၆.၈၀——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+၀.၂၂%
၂,၃၉၇.၅၀
+၅.၃၈
+၀.၂၂%
—၂,၃၉၂.၁၂၂,၃၉၆.၉၅၂,၄၂၁.၂၂၂,၃၈၂.၃၂——
Q1 2026 earnings • released • EPS beat +၂၃.၆၁% • Revenue beat +၁၀.၃၂%
See results
BIIB:NASDAQ
Biogen Inc
၁၈၇.၀၆ US$
-၁.၁၇%
(-၂.၂၂) 1D
၁၈၇.၁၇ US$
+၀.၀၆% (+၀.၁၁)
After hours
Closed: မေ ၁, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB...
Open
၁၈၉.၂၈ US$
High
၁၉၀.၅၇ US$
Low
၁၈၆.၁၄ US$
Mkt. cap
ဋေ ၂.၇၆ ထ
Avg. vol.
၁.၂၁ သန်း
Volume
၆.၉၇ သိန်း
P/E ratio
၂၀.၀၇
52-wk high
၂၀၂.၄၁ US$
52-wk low
၁၁၅.၂၈ US$
EPS
၉.၃၂ US$
Beta
၀.၁၆
Shares outstanding
၁၄.၇၆ ကုဋေ
No. of employees
၈ ထောင်
News stories
From sources across the web
GuruFocus
GuruFocus
·
ပြီးခဲ့သည့် ၁ ရက်
BIIB Maintains Rating by Citigroup -- Price Target Raised to $20
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၁ ရက်
Freedom Broker upgrades Biogen stock rating on Apellis acquisition
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၂ ရက်
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns
The Globe and Mail
The Globe and Mail
·
ပြီးခဲ့သည့် ၂ ရက်
Morgan Stanley Remains a Hold on Biogen (BIIB)
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees၇.၅ ထောင်
Founded၁၉၇၈
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitebiogen.com
Last report
၂၀၂၆ ဧ ၂၉
Fiscal Period
Q1 2026
Normalized EPS / Estimate
၃.၅၇/ (၂.၈၉ est.)USD
+၂၃.၆၁%beat
Revenue / Estimate
၂၄၇.၇၈ ဋေ/ (၂၂၄.၆၁ ဋေ est.)USD
+၁၀.၃၂%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
Revenue
၂၆၄.၅၅ ဋေ
၂၅၃.၄၇ ဋေ
၂၂၇.၉၄ ဋေ
၂၄၇.၇၈ ဋေ
Cost of goods sold
၉၄.၆၂ ကုဋေ
၅၀.၈၆ ကုဋေ
၄၄.၃၄ ကုဋေ
၆၁.၀၂ ကုဋေ
Cost of revenue
၉၄.၆၂ ကုဋေ
၅၀.၈၆ ကုဋေ
၄၄.၃၄ ကုဋေ
၆၁.၀၂ ကုဋေ
Research and development expenses
-
၄၃.၁၈ ကုဋေ
၅၀.၁၀ ကုဋေ
၄၈.၂၂ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၅၈.၁၃ ကုဋေ
၅၉.၂၈ ကုဋေ
၆၈.၅၂ ကုဋေ
၆၀.၇၃ ကုဋေ
Operating expense
၇၈.၃၇ ကုဋေ
၁၂၄.၇၅ ဋေ
၁၃၈.၈၃ ဋေ
၁၃၀.၀၂ ဋေ
Total operating expenses
၁၇၂.၉၉ ဋေ
၁၇၅.၆၁ ဋေ
၁၈၃.၁၇ ဋေ
၁၉၁.၀၄ ဋေ
Operating income
၉၁.၅၆ ကုဋေ
၇၇.၈၆ ကုဋေ
၄၄.၇၇ ကုဋေ
၅၆.၇၄ ကုဋေ
Other non operating income
-၃.၃၀ သန်း
၁.၅၈ ကုဋေ
၁.၇၄ ကုဋေ
-၁.၁၀ သန်း
EBT including unusual items
၇၄.၄၀ ကုဋေ
၅၅.၇၃ ကုဋေ
-၅.၆၀ ကုဋေ
၃၇.၇၇ ကုဋေ
EBT excluding unusual items
၈၆.၁၆ ကုဋေ
၇၄.၈၃ ကုဋေ
၄၂.၃၁ ကုဋေ
၅၃.၀၁ ကုဋေ
Income tax expense
၁၀.၉၂ ကုဋေ
၉.၀၈ ကုဋေ
-၇.၁၀ သန်း
၅.၈၂ ကုဋေ
Effective tax rate
၁၄.၆၈%
၁၆.၂၉%
၁၂.၆၈%
၁၅.၄၁%
Other operating expenses
၇.၅၀ ကုဋေ
၈.၇၂ ကုဋေ
၆.၉၉ ကုဋေ
၇.၄၂ ကုဋေ
Net income
၆၃.၄၈ ကုဋေ
၄၆.၆၅ ကုဋေ
-၄.၈၉ ကုဋေ
၃၁.၉၅ ကုဋေ
Net profit margin
၂၄.၀၀%
၁၈.၄၀%
-၂.၁၅%
၁၂.၈၉%
Earnings per share
၅.၄၇
၄.၈၁
၁.၉၉
၃.၅၇
Interest and investment income
၃.၂၃ ကုဋေ
၃.၁၆ ကုဋေ
၃.၇၂ ကုဋေ
၃.၇၉ ကုဋေ
Interest expense
-၇.၂၆ ကုဋေ
-၆.၇၄ ကုဋေ
-၆.၇၅ ကုဋေ
-၆.၇၆ ကုဋေ
Net interest expenses
-၄.၀၃ ကုဋေ
-၃.၅၈ ကုဋေ
-၃.၀၃ ကုဋေ
-၂.၉၇ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၁၁၀.၉၉ ဋေ
၉၈.၀၈ ကုဋေ
၆၄.၇၉ ကုဋေ
၇၇.၁၈ ကုဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer